Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (TSX VENTURE:BMR.H)
today announced its second quarter 2013 operational and financial results.
Operational Highlights
The directors and officers of Bradmer continue to seek out new opportunities in
the ongoing process of identifying and completing an appropriate business
transaction with a view to creating value for Bradmer and its shareholders.
During the last quarter, the Company has been actively involved in ongoing
discussions with various parties in connection with potential investment and/or
merger opportunities.
Financial Results
Amounts in US dollars, unless specified otherwise, and results prepared in
accordance with International Financial Reporting Standards ("IFRS").
For the three months ended June 30, 2013, we recorded a net loss of $27,000 or
$0.001 per common share, compared to a net loss of $38,000 or $0.002 per common
share for the quarter ended June 30, 2012 based on the same weighted average
19,659,726 outstanding shares in both quarters.
General and administrative expenses were $43,000 in the three months ended June
30, 2013 compared to $47,000 in the same quarter of the prior year. Major
expenses in 2013 consisted of consulting fees of $18,000, legal fees of $8,000,
transfer agent and stock exchange listing fees of $6,000 and directors' and
officers' liability insurance premiums of $4,000. In 2012, major expenses
included consulting fees of $18,000, insurance premiums of $14,000 and audit
fees of $6,000.
The $15,000 foreign exchange gain in the second quarter of 2013 exceeded the
$9,000 foreign exchange gain in the same quarter of 2012.
For the six months ended June 30, 2013, we recorded a net loss of $62,000 or
$0.003 per common share, compared to a net loss of $109,000 or $0.006 per common
share for the six months ended June 30, 2012 based on the same weighted average
19,659,726 outstanding shares.
General and administrative expenses were $87,000 in the six months ended June
30, 2013 compared to $109,000 in the same period of the prior year. Major
expenses in 2013 consisted of consulting fees of $36,000, legal fees of $19,000,
insurance premiums of $11,000, transfer agent and stock exchange listing fees of
$8,000 and audit fees of $9,000. In 2012, expenses included consulting fees of
$37,000, insurance premiums of $29,000, transfer agent and stock exchange
listing fees of $15,000 and audit fees of $14,000. Limits on the directors' and
officers' liability insurance were reduced from $5,000,000 to $2,000,000
accounting for the reduction in premiums in the first half of 2013.
Our operational activities for the six months ended June 30, 2013 were financed
by cash on hand. At June 30, 2013, we had working capital of $859,000, compared
to $971,000 at December 31, 2012. We had available cash of $875,000 at June 30,
2013, compared to cash of $991,000 at December 31, 2012. The decrease was
primarily due to the $62,000 operating loss incurred in the first half of 2013
and the foreign currency translation adjustments.
As at August 13, 2013 and June 30, 2013, the Company had 19,659,726 common
shares and options to purchase 1,950,000 common shares outstanding.
Bradmer Pharmaceuticals Inc.
Paul Van Damme, Chief Financial Officer
Additional information about Bradmer, including the MD&A and financial results
may be found on SEDAR at www.sedar.com.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS
DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Bradmer's common shares have not been registered under the Securities Act of
1933, as amended (the "Securities Act") or any state regulatory agency in the
United States. The resale or transfer by a U.S. investor of such common shares
of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of
Regulation S of the Securities Act or such other applicable exemption
thereunder, and other applicable state securities laws.
Except for historical information, this news release may contain forward-looking
statements, which reflect the Company's current expectation regarding future
events. These forward-looking statements involve risk and uncertainties, which
may cause but are not limited to, changing market conditions, the establishment
of corporate alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory approval process
and other risks detailed from time to time in the Company's ongoing quarterly
and annual reporting.
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Financial Position
As at
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
June 30, December 31,
2013 2012
----------------------------------------------------------------------------
(audited)
Assets
Current assets
Cash $ 874,722 $ 990,759
Amounts receivable 4,118 2,861
Prepaid expenses 9,627 5,287
----------------------------------------------------------------------------
Total assets $ 888,467 $ 998,907
----------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Current liabilities
Accounts payable and accrued liabilities $ 29,702 $ 27,440
----------------------------------------------------------------------------
Shareholders' Equity
Share capital 2,183,116 2,307,972
Contributed surplus 2,412,411 2,550,381
Accumulated other comprehensive income/(loss) 55,872 (156,515)
Deficit (3,792,634) (3,730,371)
----------------------------------------------------------------------------
Total shareholders' equity 858,765 971,467
----------------------------------------------------------------------------
Total liabilities and shareholders' equity $ 888,467 $ 998,907
----------------------------------------------------------------------------
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Comprehensive (Income)/Loss
For the six months ended June 30, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Six Months Ended Three Months Ended
June 30 June 30
2013 2012 2013 2012
----------------------------------------------------------------------------
Expenses
General and
administrative $ 86,577 $ 109,260 $ 42,543 $ 47,013
----------------------------------------------------------------------------
86,577 109,260 42,543 47,013
----------------------------------------------------------------------------
Other Income
Interest (103) (200) (52) (108)
Foreign exchange gain (24,211) (281) (15,157) (8,902)
----------------------------------------------------------------------------
(24,314) (481) (15,209) (9,010)
----------------------------------------------------------------------------
Loss for the period $ 62,263 $ 108,779 $ 27,334 $ 38,003
Other comprehensive
income (212,387) (5,210) (131,411) (75,589)
----------------------------------------------------------------------------
Comprehensive
(income)/loss for the
period $ (150,124) $ 103,569 $ (104,077) $ (37,586)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Loss per share
Basic and diluted (Note
8) $ 0.003 $ 0.006 $ 0.001 $ 0.002
----------------------------------------------------------------------------
Weighted average number
of shares outstanding 19,659,726 19,659,726 19,659,726 19,659,726
----------------------------------------------------------------------------
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders' Equity
For the six months ended June 30, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Share capital
Number of Contributed
shares Amount Warrants surplus
----------------------------------------------------------------------------
Balance, January 1,
2012 19,659,726 $ 2,257,819 $ 23,255 $ 2,471,705
Expiry of warrants - - (23,255) 23,255
Foreign currency
translation adjustment - (2,439) - (2,696)
Loss for the period - - - -
----------------------------------------------------------------------------
Balance, June 30, 2012 19,659,726 $ 2,255,380 $ - $ 2,492,264
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Balance, January 1,
2013 19,659,726 $ 2,307,972 $ - $ 2,550,381
Foreign currency
translation adjustment - (124,856) - (137,970)
Loss for the period - - - -
----------------------------------------------------------------------------
Balance, June 30, 2013 19,659,726 $ 2,183,116 $ - $ 2,412,411
----------------------------------------------------------------------------
----------------------------------------------------------------------------
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders' Equity
For the six months ended June 30, 2013 and 2012
(All amounts expressed in United States dollars)
-----------------------------------------------------------------------
-----------------------------------------------------------------------
Accumulated
Other Total
Comprehensive Shareholders'
Income/(Loss) Deficit equity
-----------------------------------------------------------------------
Balance, January 1,
2012 $ (75,798) $ (3,511,621) $ 1,165,360
Expiry of warrants - - -
Foreign currency
translation adjustment 5,210 - 75
Loss for the period - (108,779) (108,779)
-----------------------------------------------------------------------
Balance, June 30, 2012 $ (70,588) $ (3,620,400) $ 1,056,656
-----------------------------------------------------------------------
-----------------------------------------------------------------------
Balance, January 1,
2013 $ (156,515) $ (3,730,371) $ 971,467
Foreign currency
translation adjustment 212,387 - (50,439)
Loss for the period - (62,263) (62,263)
-----------------------------------------------------------------------
Balance, June 30, 2013 $ 55,872 $ (3,792,634) $ 858,765
-----------------------------------------------------------------------
-----------------------------------------------------------------------
BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Cash Flows
For the six months ended June 30, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
2013 2012
----------------------------------------------------------------------------
Cash flows from operating activities
Loss for the period $ (62,263) $ (108,779)
Adjustments for:
Foreign exchange (gain)/loss (50,439) 75
----------------------------------------------------------------------------
(112,702) (108,704)
Change in non-cash operating items
Amounts receivable (1,257) (2,163)
Prepaid expenses (4,339) 148
Accounts payable and accrued expenses 2,262 15,502
----------------------------------------------------------------------------
Decrease in cash (116,038) (126,221)
Cash at beginning of period 990,759 1,192,307
----------------------------------------------------------------------------
Cash at end of period $ 874,721 $ 1,066,086
----------------------------------------------------------------------------
----------------------------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
Bradmer Pharmaceuticals Inc.
Paul Van Damme
Chief Financial Officer
1.647.629.0136
pvandamme@bradmerpharma.com
Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From Apr 2024 to May 2024
Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From May 2023 to May 2024
